FibroBiologics, Common Financials
| FBLG Stock | 1.04 0.06 5.45% |
FibroBiologics, |
Understanding current and past FibroBiologics, Common Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of FibroBiologics, Common's financial statements are interrelated, with each one affecting the others. For example, an increase in FibroBiologics, Common's assets may result in an increase in income on the income statement.
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US31573L1052 |
| CUSIP | 31573L105 |
| Location | Texas; U.S.A |
| Business Address | 455 East Medical |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.fibrobiologics.com |
| Phone | 281 651 5150 |
FibroBiologics, Common Key Financial Ratios
FibroBiologics, Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining FibroBiologics, Common's current stock value. Our valuation model uses many indicators to compare FibroBiologics, Common value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across FibroBiologics, Common competition to find correlations between indicators driving FibroBiologics, Common's intrinsic value. More Info.FibroBiologics, Common Stock is one of the top stocks in return on equity category among its peers. It also is one of the top stocks in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value FibroBiologics, Common by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.FibroBiologics, Common Systematic Risk
FibroBiologics, Common's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. FibroBiologics, Common volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on FibroBiologics, Common correlated with the market. If Beta is less than 0 FibroBiologics, Common generally moves in the opposite direction as compared to the market. If FibroBiologics, Common Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one FibroBiologics, Common is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of FibroBiologics, Common is generally in the same direction as the market. If Beta > 1 FibroBiologics, Common moves generally in the same direction as, but more than the movement of the benchmark.
About FibroBiologics, Common Financials
What exactly are FibroBiologics, Common Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include FibroBiologics, Common's income statement, its balance sheet, and the statement of cash flows. Potential FibroBiologics, Common investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although FibroBiologics, Common investors may use each financial statement separately, they are all related. The changes in FibroBiologics, Common's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on FibroBiologics, Common's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.FibroBiologics, Common March 26, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of FibroBiologics, Common help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of FibroBiologics, Common Stock. We use our internally-developed statistical techniques to arrive at the intrinsic value of FibroBiologics, Common Stock based on widely used predictive technical indicators. In general, we focus on analyzing FibroBiologics, Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build FibroBiologics, Common's daily price indicators and compare them against related drivers.
| Information Ratio | (0.17) | |||
| Maximum Drawdown | 41.68 | |||
| Value At Risk | (8.87) | |||
| Potential Upside | 7.83 |
Complementary Tools for FibroBiologics, Stock analysis
When running FibroBiologics, Common's price analysis, check to measure FibroBiologics, Common's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy FibroBiologics, Common is operating at the current time. Most of FibroBiologics, Common's value examination focuses on studying past and present price action to predict the probability of FibroBiologics, Common's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move FibroBiologics, Common's price. Additionally, you may evaluate how the addition of FibroBiologics, Common to your portfolios can decrease your overall portfolio volatility.
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |